Effects of Up to 5 years of denosumab treatment on bone histology and histomorphometry: The FREEDOM study extension

Journal of Bone and Mineral Research

Volumn 29, Issue 9, 2014, Pages 2051-2056

  Brown, Jacques P ^a   Reid, Ian R ^b   Wagman, Rachel B ^c   Kendler, David ^d   Miller, Paul D ^e   Jensen, Jens Erik Beck ^f   Bolognese, Michael A ^g   Daizadeh, Nadia ^c   Valter, Ivo ^h   Zerbini, Cristiano A F ⁱ   Dempster, David W ^j,k  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c AMGEN INC   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e University of Colorado Health Sciences Center   (United States)

^f HVIDOVRE HOSPITAL   (Denmark)

^g Bethesda Health Research Center   (United States)

^h Center for Clinical and Basic Research   (Estonia)

ⁱ Centro Paulista de Investigacao Clinica   (Brazil)

^j Och Spine at New York Presbyterian Hospitals   (United States)

^k HELEN HAYES HOSPITAL   (United States)

more..

Author keywords

BONE HISTOMORPHOMETRY; CLINICAL TRIALS; OSTEOPOROSIS

Indexed keywords

DENOSUMAB; PLACEBO; TETRACYCLINE; BONE DENSITY CONSERVATION AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MASS; BONE REMODELING; BONE TURNOVER; CLINICAL ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CORTICAL BONE; CORTICAL THICKNESS (BONE); FEMALE; HISTOPATHOLOGY; HUMAN; LONG TERM CARE; OSSIFICATION; OSTEOID; OSTEOLYSIS; OSTEOMALACIA; OSTEOMETRY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TISSUE LEVEL; TRABECULAR BONE; URINALYSIS; BIOPSY; BONE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECTS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; STAINING; TIME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DEMOGRAPHY; FEMALE; HUMANS; STAINING AND LABELING; TETRACYCLINE; TIME FACTORS;

EID: 84906311116     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2236     Document Type: Article

References (27)

1. Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000; 157 (2): 435-48.
2. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93 (2): 165-76.
3. Udagawa N, Takahashi N, Yasuda H, et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology. 2000; 141 (9): 3478-84.
4. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998; 95 (7): 3597-602.
5. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361 (8): 756-65.
6. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008; 93 (6): 2149-57.
7. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009; 24 (1): 153-61.
8. Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012; 27 (3): 694-701.
9. Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010; 25 (10): 2256-65.
10. Brown JP, Dempster DW, Ding B, et al. Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. J Bone Miner Res. 2011; 26 (11): 2737-44.
11. Lippuner K, Roux C, Bone HG, et al. Denosumab treatment of postmenopausal women with osteoporosis for 7 years: clinical fracture results from the first 4 years of the FREEDOM extension. Osteoporos Int. 2013; 24(Suppl 1): S33- S67.
12. McClung MR, Lewiecki EM, Geller ML, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013; 24 (1): 227-35.
13. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012. update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013; 28 (1): 2-17.
14. Hauge E, Mosekilde L, Melsen F,. Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach. Bone. 1999; 25 (4): 389-95.
15. Bone HG, Chapurlat R, Brandi ML, et al. The effect of 3 or 6 years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013; 98 (11): 4483-92.
16. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY,. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90 (3): 1294-301.
17. Recker RR, Kimmel DB, Dempster D, Weinstein RS, Wronski TJ, Burr DB,. Issues in modern bone histomorphometry. Bone. 2011; 49 (5): 955-64.
18. Whyte MP, Bergfeld MA, Murphy WA, Avioli LV, Teitelbaum SL,. Postmenopausal osteoporosis. A heterogeneous disorder as assessed by histomorphometric analysis of Iliac crest bone from untreated patients. Am J Med. 1982; 72 (2): 193-202.
19. Meunier PJ, Sellami S, Briançon D, Edouard C,. Histological heterogeneity of apparently idiopathic osteoporosis. In:, DeLuca HF, Frost HM, Jee WSS, Johnston CCJ, Parfitt AM, editors. Osteoporosis: recent advances in pathogenesis and treatment. Baltimore: University Park Press; 1981.
20. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004; 19 (8): 1250-8.
21. Delmas PD, Munoz F, Black DM, et al. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res. 2009; 24 (9): 1544-51.
22. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD,. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003; 18 (6): 1051-6.
23. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD,. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res. 2004; 19 (3): 394-401.
24. Kostenuik PJ, Smith SY, Jolette J, Schroeder J, Pyrah I, Ominsky MS,. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone. 2011; 49 (2): 151-61.
25. Brown JP, Delmas PD, Arlot M, Meunier PJ,. Active bone turnover of the cortico-endosteal envelope in postmenopausal osteoporosis. J Clin Endocrinol Metab. 1987; 64 (5): 954-9.
26. Keshawarz NM, Recker RR,. Expansion of the medullary cavity at the expense of cortex in postmenopausal osteoporosis. Metab Bone Dis Relat Res. 1984; 5 (5): 223-8.
27. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010; 25 (8): 1886-94.